Enhancing PFC gamma holds great promise for addressing cognitive deficits in schizophrenia. This work led by Aarron Phensy indicates that successful therapies should account for cell type-specific patterns of gamma synchrony rather than just targeting PFC gamma oscillations in a nonspecific manner.